Key result
Low-dose rivaroxaban reduces all-cause mortality by ~17% versus standard therapy in CAD.
Why the study?
Does low-dose rivaroxaban reduce all-cause mortality compared with standard antithrombotic therapy in patients with coronary artery disease?
Meta-Analysis (n=37,709)
Does low-dose rivaroxaban reduce all-cause mortality compared with standard antithrombotic therapy in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
In patients with coronary artery disease, low-dose rivaroxaban reduces all-cause mortality, cardiovascular mortality, myocardial infarction, and ischemic stroke compared with standard antithrombotic therapy, at the cost of increased major (non-fatal) bleeding.
The optimal antithrombotic therapy (ATT) for patients with coronary artery disease (CAD) is still a matter of debate. In this regard, the role of low-dose rivaroxaban remains controversial. The authors performed a meta-analysis of randomized controlled trials (RCT) comparing low-dose rivaroxaban vs standard ATT across the spectrum of CAD. RCTs were searched through MEDLINE, EMBASE, and Cochrane databases, and international meeting proceedings. The primary endpoint was all-cause mortality. Results are reported as incidence rate ratio (IRR) of low-dose rivaroxaban vs standard ATT. Five trials including 37 709 randomized patients were identified. Low-dose rivaroxaban was associated with significantly lower rates of all-cause mortality (IRR = 0.83; 95% CI, 0.70-0.98; P = .02), driven by a significant reduction in cardiovascular mortality (IRR = 0.82; 95% CI, 0.69-0.97; P = .02). Low-dose rivaroxaban was also associated with a significant reduction in myocardial infarction (IRR = 0.88; 95% CI, 0.79-0.99; P = .04), major adverse cardiovascular events (IRR = 0.85; 95% CI, 0.76-0.95; P less than .01), and stroke (IRR = 0.71; 95% CI, 0.55-0.91; P less than .01). Stroke reduction was driven by a significant reduction in ischemic strokes (IRR = 0.60; 95% CI, 0.49-0.74; P less than .01), not offset by an increase in hemorrhagic strokes. In contrast, low-dose rivaroxaban increased major bleeding (IRR = 1.46; 95% CI, 0.99-2.17), but not fatal bleeding. In patients with CAD, low-dose rivaroxaban significantly reduces all-cause mortality, cardiovascular mortality, and stroke, but increases major bleeding compared with standard ATT.
No takes yet. Share an insight, caveat, or question.
Palmerini et al. (2026) conducted a meta-analysis in Coronary artery disease (CAD) (n=37,709). Low-dose rivaroxaban vs. Standard antithrombotic therapy (ATT) was evaluated on All-cause mortality (IRR 0.83, 95% CI 0.70-0.98, p=0.02). Low-dose rivaroxaban reduced all-cause mortality compared with standard antithrombotic therapy in CAD patients.
Synapse has enriched 10 related papers. Consider them for comparative context: